Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anacardic acid is a natural bioactive phytochemical primarily derived from the shell of the cashew nut (*Anacardium occidentale*). Chemically, it is a salicylic acid derivative with a long aliphatic side chain. It is widely recognized in biochemical research as a potent, non-competitive inhibitor of histone acetyltransferases (HATs), specifically targeting p300 and CREB-binding protein (CBP). By inhibiting HAT activity, anacardic acid modulates epigenetic gene expression, leading to anti-proliferative and pro-apoptotic effects in various cancer models, including pancreatic, breast, and prostate cancers. Research has demonstrated that it can activate the ATM-p53 signaling pathway to induce cell cycle arrest. Additionally, anacardic acid exhibits anti-inflammatory properties by inhibiting NF-κB signaling and possesses antimicrobial and antioxidant activities. While it is not currently an approved pharmaceutical drug, it is studied as a lead compound for oncology and is found in some nutraceutical products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anacardic acid.